Phase
Condition
Scar Tissue
Scleroderma
Collagen Vascular Diseases
Treatment
Placebo
Inebilizumab
Clinical Study ID
Ages 20-80 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Additional screening criteria check may apply for qualification:
ACR/European League Against Rheumatism (EULAR) criteria (2013) systemic sclerosis (SSc) diagnostic criteria satisfied.
Skin thickening score based on the mRTSS between 10 and 22 inclusive.
Exclusion
Exclusion Criteria:
Additional screening criteria check may apply for qualification:
Pulmonary hypertension associated with SSc.
Presence of a serious, SSc-related concurrent illness other than interstitialpneumonia.
Finding of inadequate respiratory reserve capacity.
Past history of rituximab, blinatumomab, obinutuzumab, or ofatumumab.
Presence of a clinically significant active infection requiring antimicrobialtherapy.
A past history of cancer.
Past history of a recurrent, clinically significant infection.
Past history of severe allergy or anaphylactic reaction to a biologic drug product.
Treatment with live vaccine within a certain period (inactivated vaccine isacceptable).
Study Design
Connect with a study center
University of Fukui Hospital
Yoshida-gun, Fukui 910-1193
JapanActive - Recruiting
Kanazawa University Hospital
Kanazawa, Ishikawa 920-8641
JapanActive - Recruiting
St. Marianna University Hospital
Kawasaki-shi, Kanagawa 216-8511
JapanActive - Recruiting
The University of Tokyo Hospital
Bunkyo-ku, Tokyo 113-8655
JapanActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.